8-p-Coumaroylharpagide

8-p-Coumaroylharpagide at a Glance

8-p-Coumaroylharpagide is a minor iridoid glycoside of devil’s claw (Harpagophytum). Structurally it is the p-coumaroyl ester of harpagide — the same core molecule that, esterified with cinnamic acid, becomes harpagoside, the compound devil’s-claw extracts are standardised to. So it sits one acyl group away from the herb’s headline marker.

As an isolate it is data-thin. The little direct evidence there is comes from a small number of in-vitro studies: it lowers epidermal COX-2 expression about as much as harpagoside does ^{1Reference 1Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (Devil’s Claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}, and it weakly inhibits human leukocyte elastase ^{2Reference 2Boje K et al. · 2003In vitroNew and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastaseView study →}. There are no human trials of the isolated compound, and no pharmacokinetic dataset. Its best-documented practical role is not pharmacological at all but analytical — as a chemotaxonomic marker that helps distinguish Harpagophytum species ^{6Reference 6Brendler T · 2021ReviewFrom Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum spp.)View study →}.

The anti-inflammatory reputation attached to “devil’s claw” belongs to the whole standardised root extract, and is attributed chiefly to the harpagoside-marked iridoid complex — not to this ester on its own ^{5,7Reference 5Mncwangi N et al. · 2012ReviewDevil’s Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →Reference 7Huang TH et al. · 2006Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappaB activationView study →}.

8-Coumaroylharpagide Among the Devil’s-Claw Iridoids

This molecule is best understood by its family relationships, because almost everything documented about it is comparative.

It is an ester of harpagide. Harpagide is the parent iridoid; attaching different acyl groups to its 8-position gives the devil’s-claw ester series. Attach cinnamic acid and you get harpagoside (the standardisation marker); attach p-coumaric acid (a hydroxycinnamic acid) and you get 8-p-coumaroylharpagide; the ferulic-acid ester is 8-feruloylharpagide. They are near-isomers differing only in that acyl cap, which is why they co-occur and behave similarly in several assays.

A co-marker, not the marker. In the one in-vitro study to test the devil’s-claw glycosides side by side on skin, 8-p-coumaroylharpagide reduced epidermal COX-2 expression comparably to harpagoside, while the un-esterified parent harpagide did the opposite and raised COX-2 — leading the authors to conclude the extract’s effect depends on the ratio of these compounds rather than harpagoside content alone ^{1Reference 1Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (Devil’s Claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}. That makes the coumaroyl ester a plausible positive contributor to the whole-extract effect, though the point rests on a single skin-model study.

A species fingerprint. Its most reliable documented use is chemotaxonomic. 8-p-Coumaroylharpagide runs at roughly 0.7–1.4% of dry weight in Harpagophytum zeyheri (the cheaper grapple plant) but is low to near-absent in H. procumbens, the species that carries the clinical evidence — so the harpagoside-to-8-PCHG ratio is used to tell authentic material from the zeyheri substitute ^{6Reference 6Brendler T · 2021ReviewFrom Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum spp.)View study →}. In practice, then, a high 8-PCHG reading is a flag for the substitute species rather than a mark of quality.

The Ajuga connection. The harpagide esters are not unique to devil’s claw — they also occur in bugle (Ajuga spp., Lamiaceae), where iridoids of this family have documented ecological and cardiovascular-pharmacology roles. Importantly, most of that Ajuga work is on the closely related 8-O-acetylharpagide (the acetyl ester), not the p-coumaroyl ester specifically — see Its Role in Plants & Insects for that honesty caveat.

Isolate data on 8-p-coumaroylharpagide itself remain thin, and there is no human data on it at all; the anti-inflammatory story is the whole extract’s.

What It's Used For

Direct evidence for the isolated molecule is limited to a couple of in-vitro studies and comparisons with its siblings. There is no animal or human trial of the isolate.

Evidence by IndicationStrength of support · Beta

Support is an experimental score — weighted by study type (human > animal > in vitro) and volume. A beta, not a validated metric. Every row here rests on in-vitro isolate or whole-extract data, so scores are low by design.

01Anti-inflammatory (COX-2, as extract co-marker)Shaky22%Single in-vitro skin study; reduces COX-2 like harpagoside ^{1Reference 1Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (Devil’s Claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}

02Leukocyte elastase inhibitionShaky14%One in-vitro assay; weak, dose-dependent ^{2Reference 2Boje K et al. · 2003In vitroNew and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastaseView study →}

Mechanisms

The load-bearing point is comparative: 8-p-coumaroylharpagide behaves like harpagoside (COX-2 down) and unlike its own parent harpagide (COX-2 up), so within the extract it reads as a positive contributor — but its individual mechanism is barely characterised, and the clinical anti-inflammatory record belongs to harpagoside and the whole extract.

Pharmacokinetics

No pharmacokinetic dataset exists for 8-p-coumaroylharpagide. As a polar iridoid glycoside, it is expected to share the class limitation seen across devil’s-claw iridoids — poor oral bioavailability, since the intact glycoside is largely not absorbed and is subject to gut-microbial hydrolysis of the sugar before any aglycone reaches circulation. Absorption, metabolism, active metabolites and half-life for this specific ester are all unstudied, which is itself a reason to treat in-vitro potencies cautiously: the concentrations used in the COX-2 and elastase assays are not shown to be reachable in tissue from oral extract dosing.

Clinical Trials

There are no clinical trials of isolated 8-p-coumaroylharpagide. Human evidence exists only for standardised whole devil’s-claw root extract (dosed to its harpagoside marker), within which this compound is a minor, un-isolated co-constituent ^{5,7Reference 5Mncwangi N et al. · 2012ReviewDevil’s Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →Reference 7Huang TH et al. · 2006Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappaB activationView study →}.

Last checked: July 2026.

Isolate vs. Plant Studies

This molecule sits firmly on the plant/extract side of the ledger. Everything of clinical relevance about “devil’s claw” — the randomised trials in low-back pain and osteoarthritis — used standardised whole-root extracts dosed to harpagoside, not this ester ^{5,7Reference 5Mncwangi N et al. · 2012ReviewDevil’s Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →Reference 7Huang TH et al. · 2006Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappaB activationView study →}. The only isolate data for 8-p-coumaroylharpagide are the two in-vitro studies above ^{1,2Reference 1Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (Devil’s Claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →Reference 2Boje K et al. · 2003In vitroNew and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastaseView study →}, and even the more suggestive of them (COX-2) is interpreted as evidence about the ratio of constituents in the whole extract rather than a stand-alone drug effect ^{1Reference 1Abdelouahab N · 2008In vitroEffect of the major glycosides of Harpagophytum procumbens (Devil’s Claw) on epidermal cyclooxygenase-2 (COX-2) in vitroView study →}. The Ajuga pharmacology often cited for “harpagide esters” is, on close reading, mostly for the acetyl ester (8-O-acetylharpagide), a different molecule ^{3,4Reference 3Breschi MC et al. · 1992Vasoconstrictor activity of 8-O-acetylharpagide from Ajuga reptansView study →Reference 4Elbrecht A et al. · 1996Elbrecht A, Chen Y, Jurgens T, Hensens OD, Zink DL, Beck HT, Balick MJ, Borris R (1996). 8-O-acetylharpagide is a nonsteroidal ecdysteroid agonist. Insect Biochemistry and Molecular Biology. https://pubmed.ncbi.nlm.nih.gov/8969463/View study →}. So the transferability caveat is strong: do not read whole-extract efficacy, or a sibling ester’s activity, as evidence for isolated 8-p-coumaroylharpagide.

Its Role in Plants & Insects

Iridoids of the harpagide-ester family function as plant chemical defences, and the bugle genus Ajuga is the classic case. The closely related 8-O-acetylharpagide, isolated from Ajuga reptans, is a nonsteroidal ecdysteroid agonist — it binds the insect ecdysteroid receptor and mimics the moulting hormone (EC₅₀ ≈ 22 µM in a transactivation assay), a mode of action that can disrupt insect development and underlies the use of Ajuga extracts as insect growth inhibitors ^{4Reference 4Elbrecht A et al. · 1996Elbrecht A, Chen Y, Jurgens T, Hensens OD, Zink DL, Beck HT, Balick MJ, Borris R (1996). 8-O-acetylharpagide is a nonsteroidal ecdysteroid agonist. Insect Biochemistry and Molecular Biology. https://pubmed.ncbi.nlm.nih.gov/8969463/View study →}. The same acetyl ester also showed vasoconstrictor / smooth-muscle activity in guinea-pig tissue, offered as a rationale for Ajuga’s traditional uses ^{3Reference 3Breschi MC et al. · 1992Vasoconstrictor activity of 8-O-acetylharpagide from Ajuga reptansView study →}.

The honesty caveat matters here: those biological roles are documented for 8-O-acetylharpagide, not for the p-coumaroyl ester specifically. 8-p-Coumaroylharpagide is a plausible participant in the same defensive iridoid chemistry, but its own ecological or insect-hormone activity has not been separately demonstrated. As always, an insect-hormone or plant-defence role says nothing about human pharmacology.

Prevalence in Nature

8-p-Coumaroylharpagide is a root iridoid of devil’s claw (Harpagophytum), concentrated in the secondary storage roots (tubers) where the genus stores its bitter iridoids — alongside sibling iridoids such as harpagoside and procumbide ^{5Reference 5Mncwangi N et al. · 2012ReviewDevil’s Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →}. Its distribution across the two commercial species is the headline fact: it reaches roughly 0.7–1.4% of dry weight in Harpagophytum zeyheri (the grapple plant) but is low to near-absent in H. procumbens, the species that carries the pharmacological evidence ^{6Reference 6Brendler T · 2021ReviewFrom Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum spp.)View study →}. Because of that split it is a practical species marker — the harpagoside-to-8-PCHG ratio flags zeyheri substitution in traded material ^{6Reference 6Brendler T · 2021ReviewFrom Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum spp.)View study →}.

Beyond Harpagophytum, harpagide esters of this family occur in bugle (Ajuga spp., Lamiaceae) ^{3,4Reference 3Breschi MC et al. · 1992Vasoconstrictor activity of 8-O-acetylharpagide from Ajuga reptansView study →Reference 4Elbrecht A et al. · 1996Elbrecht A, Chen Y, Jurgens T, Hensens OD, Zink DL, Beck HT, Balick MJ, Borris R (1996). 8-O-acetylharpagide is a nonsteroidal ecdysteroid agonist. Insect Biochemistry and Molecular Biology. https://pubmed.ncbi.nlm.nih.gov/8969463/View study →}. Absolute concentrations outside the two devil’s-claw species are not well quantified.

Discovery & Synthesis

8-p-Coumaroylharpagide was characterised as part of the devil’s-claw iridoid complex during twentieth-century phytochemical study of Harpagophytum storage roots, and was profiled explicitly among the root’s iridoid and phenylethanoid glycosides in the elastase-screening work of Boje, Lechtenberg and Nahrstedt (2003) ^{2Reference 2Boje K et al. · 2003In vitroNew and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastaseView study →}. Its name is purely descriptive: it is harpagide (the parent iridoid, itself named for Harpagophytum) bearing a p-coumaroyl ester at the 8-position — the p-coumaric-acid analogue of harpagoside’s cinnamoyl group.

There is no notable total synthesis on record; as a minor, un-commercialised iridoid it is obtained, when needed, by chromatographic isolation from devil’s-claw (or Ajuga) plant material for analytical and research use rather than manufactured. It is not produced as a stand-alone supplement ingredient.

Patents: not yet researched.

Toxicity & Safety

8-p-Coumaroylharpagide carries a low flag. It is a minor iridoid within a herb — devil’s claw — with a long record of use and generally good tolerability at customary extract doses, and there is no isolate-specific toxicity signal. The honest qualifier is that the isolated compound has not been characterised for safety: there is no isolate toxicology, genotoxicity or repeat-dose dataset, so the “low” rating is inferred from the whole herb’s safety profile, not measured for the molecule.

Safety at a Glance

✅ Low / no toxicity

• No isolate-specific toxicity signal, and the parent herb (devil’s claw) is generally well tolerated at customary standardised-extract doses.
• Herb-level cautions carry over. Devil’s claw itself is cautioned in active peptic ulcer / gastritis (bitter iridoids stimulate gastric secretion) and its extracts have theoretical interaction potential — those decisions belong to the herb and product pages, where intake is decided.
• The isolate is uncharacterised. No dedicated toxicology, genotoxicity, pharmacokinetic or reproductive-toxicity data exist for 8-p-coumaroylharpagide specifically; absence of a signal is not evidence of safety.

Reproductive and pregnancy safety have not been assessed for this isolated compound; devil’s-claw preparations are conventionally avoided in pregnancy at the herb level as a precaution, and that decision belongs to the herb/product monograph rather than this molecule page.

Dosage

There is no established or recommended dose for isolated 8-p-coumaroylharpagide — it is not sold or used as an isolate. Human exposure is entirely indirect, as one minor iridoid inside a standardised devil’s-claw root extract, which is dosed to its harpagoside marker (commonly about 50–100 mg harpagoside per day, delivered by roughly 2–4.5 g of extract) ^{5,7Reference 5Mncwangi N et al. · 2012ReviewDevil’s Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbensView study →Reference 7Huang TH et al. · 2006Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappaB activationView study →} — not to this compound. In the chiefly traded species (H. procumbens) the 8-p-coumaroylharpagide content is low to begin with ^{6Reference 6Brendler T · 2021ReviewFrom Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum spp.)View study →}.

These are research and standardisation figures for the parent extract, not a personal recommendation for the isolated molecule.

References

1. Abdelouahab N, Heard C (2008). Effect of the major glycosides of Harpagophytum procumbens (Devil’s Claw) on epidermal cyclooxygenase-2 (COX-2) in vitro. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/18412394/
2. Boje K, Lechtenberg M, Nahrstedt A (2003). New and known iridoid- and phenylethanoid glycosides from Harpagophytum procumbens and their in vitro inhibition of human leukocyte elastase. Planta Medica. https://pubmed.ncbi.nlm.nih.gov/14598207/
3. Breschi MC, Martinotti E, Catalano S, Flamini G, Morelli I, Pagni AM (1992). Vasoconstrictor activity of 8-O-acetylharpagide from Ajuga reptans. Journal of Natural Products. https://pubmed.ncbi.nlm.nih.gov/1431938/
4. Elbrecht A, Chen Y, Jurgens T, Hensens OD, Zink DL, Beck HT, Balick MJ, Borris R (1996). 8-O-acetylharpagide is a nonsteroidal ecdysteroid agonist. Insect Biochemistry and Molecular Biology. https://pubmed.ncbi.nlm.nih.gov/8969463/
5. Mncwangi N, Chen W, Vermaak I, Viljoen AM, Gericke N (2012). Devil’s Claw — a review of the ethnobotany, phytochemistry and biological activity of Harpagophytum procumbens. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/22940241/
6. Brendler T (2021). From Bush Medicine to Modern Phytopharmaceutical: A Bibliographic Review of Devil’s Claw (Harpagophytum spp.). Pharmaceuticals (Basel). https://pubmed.ncbi.nlm.nih.gov/34451822/
7. Huang TH, Tran VH, Duke RK, Tan S, Chrubasik S, Roufogalis BD, Duke CC (2006). Harpagoside suppresses lipopolysaccharide-induced iNOS and COX-2 expression through inhibition of NF-kappaB activation. Journal of Ethnopharmacology. https://pubmed.ncbi.nlm.nih.gov/16203115/

View all 7 references▾